US healthcare giant Johnson & Johnson has announced new data from the investigational Phase III MajesTEC-3 study showing the ...
The UK government has announced that the 2026 payment rate for newer medicines under the Voluntary Scheme for Branded ...
Privately-held BlossomHill Therapeutics, a US biopharma focused on the design and development of next-generation medicines ...
Clinical-stage biotech D3 Bio announced the completion of a $108 million Series B financing round, adding to the continuous ...
Swiss pharma giant Novartis’ has announced results showing that one in four patients with hormone receptor-positive, human ...
US AI-focused start-up Formation Bio has entered a deal with Lynk Pharmaceuticals for worldwide rights, excluding Greater ...
The US regulator has approved Waskyra (etuvetidigene autotemcel), the first gene-correcting therapy for Wiskott-Aldrich ...
Headquartered in Antwerp, Belgium, with an additional site in Denmark (Aarhus). The company is developing macrophage-targeted ...
EpilepsyGTx’s $33 million Series A to advance single dose gene therapy for focal refractory epilepsy
UK-based EpilepsyGTx, a biotech focused on research and development of gene therapies to treat refractory epilepsy, has raised $33 million in a Series A financing to advance its lead program EPY201 ...
A senior-level conference focused on the strategies and operating models shaping the next phase of the biopharma industry.
The US Food and Drug Administration has approved a US-manufactured version of Augmentin XR (amoxicillin-clavulanate potassium) through its new Commissioner’s National Priority Voucher pilot, ...
The US Food and Drug Administration (FDA) yesterday issued the final guidance, “Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Products, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback